Verisante Technology (VRS) Stock Price, News & Analysis

Company Overview

Verisante Technology Inc., a medical device company, engages in commercializing skin cancer detection systems. The company's products comprise Verisante Aura, which helps in the detection of various forms of skin cancer, including basal cell and squamous cell carcinoma, and melanoma; and Verisante Core for the detection of lung, cervical, gastrointestinal, and colo-rectal cancers. It also owns all the rights to the ClearVu and ClearVu Elite endoscopy systems for the detection of lung cancer. Verisante Technology has a licensing agreement with the BC Cancer Agency for the manufacture, distribution, and sale of products based on patented skin cancer detection technology. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology Inc. in January 2011. Verisante Technology Inc. was founded in 2006 and is based in Richmond, Canada.

Key Stats

• Today's Range: C$0.02 to C$0.02
• 50-Day Range: C$0.02 to C$0.02
• 52-Week Range: C$0.01 to C$0.06
• Volume: 197,000 shs
• Average Volume: 256,747 shs
• Market Capitalization: C$1.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: CVE:VRS
• CIK: N/A
• Web: verisign.com
• Phone: +1-604-6050507
• Fax: N/A
• Employees: 920
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 98,616,000
• Free Float: N/A
• Market Cap: C$1.97 million
• Optionable: Not Optionable
• Beta: N/A